Advanced search
Publication Cover
Drug Delivery Volume 24, 2017 - Issue 1
Submit an article Journal homepage
1,614
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel

Anne Steinsa Cancer Center Amsterdam, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Academic Medical Center, Amsterdam, The Netherlands; ;b Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands; View further author information
,
Eva A. Ebbinga Cancer Center Amsterdam, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Academic Medical Center, Amsterdam, The Netherlands; ;b Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands; View further author information
,
Marcel C. M. Pistoriusc Department of Hospital Pharmacy, Academic Medical Center, Amsterdam, The Netherlands; View further author information
,
Cynthia Waasdorpa Cancer Center Amsterdam, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Academic Medical Center, Amsterdam, The Netherlands; View further author information
,
Kausilia K. Krishnadatha Cancer Center Amsterdam, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Academic Medical Center, Amsterdam, The Netherlands; ;d Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands; View further author information
,
Jan Paul Medemaa Cancer Center Amsterdam, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Academic Medical Center, Amsterdam, The Netherlands; ;e Cancer Genomics Center, Center for Molecular Medicine, Utrecht, The NetherlandsView further author information
,
Johanna W. Wilminkb Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands; View further author information
,
Ron A. A. Mathôtc Department of Hospital Pharmacy, Academic Medical Center, Amsterdam, The Netherlands; View further author information
,
Maarten F. Bijlsmaa Cancer Center Amsterdam, Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Academic Medical Center, Amsterdam, The Netherlands; View further author information
&
Hanneke W. M. van Laarhovenb Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands; Correspondence[email protected]
View further author information
 show all
Pages 1801-1810 | Received 11 Sep 2017, Accepted 14 Nov 2017, Published online: 24 Nov 2017

Related Research Data

Tumor Angiogenesis: Therapeutic Implications
Source: Massachusetts Medical Society
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment
Source: American Association for Cancer Research (AACR)
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Source: Elsevier BV
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Source: Elsevier BV
Targeted inhibition of VEGF receptor 2: an update on ramucirumab
Source: Informa Healthcare
SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice
Source: BMJ
nab-Paclitaxel mechanisms of action and delivery.
Source: Elsevier BV
Pharmacokinetics of combined doxorubicin and paclitaxel in mice
Source: Elsevier BV
Intraperitoneal administration of paclitaxel solubilized with poly(2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) for peritoneal dissemination of gastric cancer.
Source: Wiley
Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel
Source: Taylor & Francis
Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia.
Source: Springer Science and Business Media LLC
Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Source: American Society of Clinical Oncology (ASCO)
Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration
Source: Springer Science and Business Media LLC
Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma
Source: SAGE Publishing
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Source: Elsevier BV
Anti-VEGF– and anti-VEGF receptor–induced vascular alteration in mouse healthy tissues
Source: NATL ACAD SCIENCES
Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials
Source: Maney Publishing
Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis.
Source: Springer Science and Business Media LLC
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
Source: American Society of Clinical Oncology (ASCO)
The mechanisms that regulate the localization and overexpression of VEGF receptor-2 are promising therapeutic targets in cancer biology.
Source: Ovid Technologies (Wolters Kluwer Health)
Tumor-Specific Expression of Vascular Endothelial Growth Factor Receptor 2 but Not Vascular Endothelial Growth Factor or Human Epidermal Growth Factor Receptor 2 Is Associated With Impaired Response to Adjuvant Tamoxifen in Premenopausal Breast Cancer
Source: American Society of Clinical Oncology (ASCO)
Molecular mechanisms and clinical applications of angiogenesis
Source: Springer Science and Business Media LLC
Albumin-Binding and Angiogenic Domains of SPARC Located at Its C-Terminus.
Source: American Association for Cancer Research
Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment.
Source: American Association for Cancer Research (AACR)
Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer
Source: Wiley
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
Source: American Physiological Society
Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer.
Source: Wiley

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.